top of page

返回

ALS, 肌萎縮側索硬化症, 研究, 罕見病, 藥物

Breakthrough ALS Treatment Approved in Japan: Mecoba

Japan's health ministry has approved the production and sale of mecobalamin, a new drug for amyotrophic lateral sclerosis (ALS), which significantly extends patient survival by over 500 days compared to existing treatments. Initially proposed for approval in 2015 by Eisai Co., the drug underwent a doctor-led clinical trial involving patients within a year of ALS onset at 25 facilities. The trial showed that mecobalamin, when administered earlier, resulted in a longer survival period than riluzole, which typically extends life by about 90 days.

The research team noted a potential synergistic effect when mecobalamin was used alongside existing treatments, raising hopes for halting disease progression. Eisai's application for government approval was re-submitted early this year, and the health ministry's expert panel recently approved it, raising hopes among ALS patients for better disease management and potential future cures.


For more information visit: https://www.japantimes.co.jp/news/2024/09/24/japan/science-health/japan-new-als-drug-approve/

Codex offers hereditary genetic tests for cancer and neuro diseases, and comprehensive genomic profiling for cancer treatments. The services provided by Codex Genetics are for research use only, and they are not suitable for diagnostic and/or treatment use, unless otherwise instructed by licensed medical professionals. 

科德施提供與腦神經退化和癌症基因相關的測試。 除非有醫療專業人員另行指示,此網站的服務只供研究用途,並不供作診斷或治療任何疾病之用。

  • alt.text.label.Facebook
  • alt.text.label.LinkedIn
  • alt.text.label.Instagram

Office Hours:
Monday to Friday 10:00 – 18:00
Closed on Saturdays, Sundays and public holidays.
If you need special arrangements, please contact us during office hours.

Privacy policy
​Terms of Use
Contact us

©2024 by Codex Genetics Limited

bottom of page